Expand all sections

Exenatide

Bydureon

Extended indication Extension of indication to include the treatment of type 2 diabetes in adolescents and children aged
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Exenatide
Domain Metabolism and Endocrinology
Reason of inclusion Indication extension
Main indication Diabetes
Extended indication Extension of indication to include the treatment of type 2 diabetes in adolescents and children aged 10 years and above
Proprietary name Bydureon
Manufacturer AstraZeneca
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Decentralised
ATMP No
Submission date August 2021
Expected Registration June 2022
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.